Nkarta, which is developing cell therapy treatments for cancer, has emerged from stealth with $114m in a round featuring Novo, Amgen Ventures and SR One.

US-based oncology therapy developer Nkarta Therapeutics completed its $114m series B round yesterday, securing capital from investors including pharmaceutical firms Amgen, Novo and GlaxoSmithKline (GSK). Samsara BioCapital led the round, which included Deerfield Management, Life Science Partners, New Enterprise Associates (NEA), Logos Capital and RA Capital Management, while Amgen and GSK took part through subsidiaries…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.